Cormedix affirms FY2026 sales guidance at $325M–$345M
Cormedix (NASDAQ: CRMD) affirms FY2026 sales guidance of $325.000M–$345.000M, compared with a $334.089M estimate, with the range unchanged from the prior outlook.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.